Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
J Antimicrob Chemother. 2011 Dec;66 Suppl 6:vi3-12. doi: 10.1093/jac/dkr453.
To describe total outpatient systemic antibiotic use in Europe from 1997 to 2009 and to analyse statistically trends of total use and composition of use over time.
For the period 1997-2009, data on outpatient use of systemic antibiotics aggregated at the level of the active substance were collected and expressed in defined daily doses (WHO, version 2011) and packages per 1000 inhabitants per day (DID and PID, respectively). Outpatient antibiotic (ATC J01) use in DID in the 33 European countries able to deliver valid data was analysed using longitudinal and compositional data analyses.
Total outpatient antibiotic use in 2009 varied by a factor of 3.8 between the countries with the highest (38.6 DID in Greece) and lowest (10.2 DID in Romania) use. For Europe, a significant increase was found in total outpatient antibiotic use, as well as a significant seasonal variation, which decreased over time from 1997 to 2009. Relative use of penicillins and quinolones significantly increased over time with respect to sulphonamides and trimethoprim, and relative use of quinolones increased with respect to macrolide/lincosamide/streptogramin as well. More detailed analyses of these major antibiotic subgroups will be described in separate papers.
Outpatient antibiotic use in Europe measured as DID has increased since 1997, whereas seasonal variation has decreased over time. European Surveillance of Antimicrobial Consumption (ESAC) data on outpatient antibiotic use in Europe enable countries to audit their antibiotic use. Complemented by longitudinal and compositional data analyses, these data provide a tool for assessing public health strategies aimed at reducing antibiotic resistance and optimizing antibiotic prescribing.
描述 1997 年至 2009 年欧洲的门诊全身用抗生素使用情况,并分析随时间推移的总使用量和使用构成的统计趋势。
在 1997-2009 年期间,收集了汇总到活性物质水平的门诊全身用抗生素使用数据,并以世界卫生组织(2011 年版)的限定日剂量(DDD)和每日每千人口包装数(DID 和 PID)表示。使用纵向和成分数据分析,对 33 个能够提供有效数据的欧洲国家的门诊抗生素(ATC J01)DDD 使用情况进行了分析。
2009 年,各国门诊抗生素使用量相差 3.8 倍,最高(希腊 38.6 DDD)和最低(罗马尼亚 10.2 DDD)国家之间差异显著。欧洲门诊抗生素总使用量呈显著上升趋势,且具有季节性变化,2009 年与 1997 年相比有所下降。与磺胺类药物和甲氧苄啶相比,青霉素类和喹诺酮类的相对使用量随时间推移而增加,而与大环内酯类/林可酰胺类/链阳性菌素类相比,喹诺酮类的相对使用量也增加。这些主要抗生素亚组的更详细分析将在单独的论文中描述。
自 1997 年以来,欧洲以 DID 衡量的门诊抗生素使用量有所增加,而季节性变化随时间推移而减少。欧洲抗菌药物监测系统(ESAC)的欧洲门诊抗生素使用数据使各国能够对其抗生素使用情况进行审核。结合纵向和成分数据分析,这些数据为评估旨在减少抗生素耐药性和优化抗生素处方的公共卫生策略提供了工具。